Ⅷ C and ⅧR: Ag were measured in 24 mothers of patients with hemophilia A in present studies.The rate of detecting hemophilia A carrier by using these methods was more than 90%.There are 10% mistake rate reported by ...Ⅷ C and ⅧR: Ag were measured in 24 mothers of patients with hemophilia A in present studies.The rate of detecting hemophilia A carrier by using these methods was more than 90%.There are 10% mistake rate reported by other investigatoro in diagnosis of hemophilia A carrier based on the Ⅷ: C and ⅧR: Ag determination. Although these method is less precise than that of gene diagnosis in detecting hemophilia A carrier, the former is much simple and practicable. Conditionally, the gene diaguosis is not currently available in this country.The measurement of Ⅷ: C and ⅧR:Ag is a good screening method with high detecting rate for carrier detection.展开更多
目的对一期凝固法凝血因子Ⅷ活性(FⅧ:C)检测系统进行性能验证。方法依据中国合格评定国家认可委员会(CNAS)-GL037《临床化学定量检验程序性能验证指南》及相关卫生行业标准提供的方案,对ACL TOP 700全自动凝血分析仪及其配套试剂一期...目的对一期凝固法凝血因子Ⅷ活性(FⅧ:C)检测系统进行性能验证。方法依据中国合格评定国家认可委员会(CNAS)-GL037《临床化学定量检验程序性能验证指南》及相关卫生行业标准提供的方案,对ACL TOP 700全自动凝血分析仪及其配套试剂一期凝固法测定FⅧ:C精密度、正确度、准确度、线性范围、可报告范围、定量检出限、医学决定水平不精密度、携带污染率、抗干扰实验及参考范围进行验证。结果批内不精密度变异系数(CV)值为1.8%~4.1%(≤5%),批间不精密度CV值为3.5%~3.9%(≤10%)。正确度:偏倚为-1.3%(在±10%范围内)。准确度:两个浓度室间质评物质偏倚差分别为1.81%和-0.87%(均在±10%范围内)。线性范围:14.6%~142.7%(R^(2)=0.9939)。定量检出限:1%,与厂商声称相符。医学决定水平(1%、3%、5%)不精密度为5.1%~8.6%(≤10%)。稀释验证:在32倍及以下稀释时,R值均在80%~120%之间。可报告范围:1%~428.1%。携带污染率:0(≤10%)。干扰实验结果显示有较强的抗干扰能力。参考范围(50%~150%)验证:20例表观健康人有19例检测结果在参考范围内,验证通过。结论一期凝固法Ⅷ因子活性检测系统精密度、正确度、准确度、线性范围、可报告范围、检出限、医学决定水平不精密度、携带污染率、抗干扰能力、参考范围验证等各项性能指标均满足国际标准化组织(ISO)15189的要求,可用于临床检测。展开更多
We report a case of successful treatment of chronic hepatitis C infection with telaprevir-based triple therapy in a patient with hemophilia A complicated by factor Ⅷ inhibitor. A twenty-two years old male with heredi...We report a case of successful treatment of chronic hepatitis C infection with telaprevir-based triple therapy in a patient with hemophilia A complicated by factor Ⅷ inhibitor. A twenty-two years old male with hereditary hemophilia A and high-titer factor Ⅷ inhibitor was taking maintenance doses of recombinant factor Ⅷ. He visited our clinic for treatment of his chronic hepatitis C with the newly instituted protease inhibitor based therapy. He was diagnosed with hepatitis C genotype 1a at one year of age. He was initiated on telaprevir, ribavirin and peg-interferon for treatment of hepatitis C and qualified for response-guided therapy. He completed treatment at 24 wk with minimal adverse effects. Notably, after 4 wk of hepatitis C treatment, his factor Ⅷ inhibitor screen was negative and the dose for recombinant factor Ⅷ decreased by half of the initial dosing before he was treated for hepatitis C. We suspect that suppressing hepatitis C may help decrease factor Ⅷ inhibitor level and the need for recombinant factor Ⅷ.展开更多
文摘Ⅷ C and ⅧR: Ag were measured in 24 mothers of patients with hemophilia A in present studies.The rate of detecting hemophilia A carrier by using these methods was more than 90%.There are 10% mistake rate reported by other investigatoro in diagnosis of hemophilia A carrier based on the Ⅷ: C and ⅧR: Ag determination. Although these method is less precise than that of gene diagnosis in detecting hemophilia A carrier, the former is much simple and practicable. Conditionally, the gene diaguosis is not currently available in this country.The measurement of Ⅷ: C and ⅧR:Ag is a good screening method with high detecting rate for carrier detection.
文摘目的对一期凝固法凝血因子Ⅷ活性(FⅧ:C)检测系统进行性能验证。方法依据中国合格评定国家认可委员会(CNAS)-GL037《临床化学定量检验程序性能验证指南》及相关卫生行业标准提供的方案,对ACL TOP 700全自动凝血分析仪及其配套试剂一期凝固法测定FⅧ:C精密度、正确度、准确度、线性范围、可报告范围、定量检出限、医学决定水平不精密度、携带污染率、抗干扰实验及参考范围进行验证。结果批内不精密度变异系数(CV)值为1.8%~4.1%(≤5%),批间不精密度CV值为3.5%~3.9%(≤10%)。正确度:偏倚为-1.3%(在±10%范围内)。准确度:两个浓度室间质评物质偏倚差分别为1.81%和-0.87%(均在±10%范围内)。线性范围:14.6%~142.7%(R^(2)=0.9939)。定量检出限:1%,与厂商声称相符。医学决定水平(1%、3%、5%)不精密度为5.1%~8.6%(≤10%)。稀释验证:在32倍及以下稀释时,R值均在80%~120%之间。可报告范围:1%~428.1%。携带污染率:0(≤10%)。干扰实验结果显示有较强的抗干扰能力。参考范围(50%~150%)验证:20例表观健康人有19例检测结果在参考范围内,验证通过。结论一期凝固法Ⅷ因子活性检测系统精密度、正确度、准确度、线性范围、可报告范围、检出限、医学决定水平不精密度、携带污染率、抗干扰能力、参考范围验证等各项性能指标均满足国际标准化组织(ISO)15189的要求,可用于临床检测。
文摘We report a case of successful treatment of chronic hepatitis C infection with telaprevir-based triple therapy in a patient with hemophilia A complicated by factor Ⅷ inhibitor. A twenty-two years old male with hereditary hemophilia A and high-titer factor Ⅷ inhibitor was taking maintenance doses of recombinant factor Ⅷ. He visited our clinic for treatment of his chronic hepatitis C with the newly instituted protease inhibitor based therapy. He was diagnosed with hepatitis C genotype 1a at one year of age. He was initiated on telaprevir, ribavirin and peg-interferon for treatment of hepatitis C and qualified for response-guided therapy. He completed treatment at 24 wk with minimal adverse effects. Notably, after 4 wk of hepatitis C treatment, his factor Ⅷ inhibitor screen was negative and the dose for recombinant factor Ⅷ decreased by half of the initial dosing before he was treated for hepatitis C. We suspect that suppressing hepatitis C may help decrease factor Ⅷ inhibitor level and the need for recombinant factor Ⅷ.
